Previous 10 | Next 10 |
This article explains the reasons behind the movement in a selection of the largest U.S. cash merger arbitrage spreads from the past week as calculated by Merger Arbitrage Limited. We analyze the attractiveness and profitability of each spread going forward and indicate the trading position or...
Merger activity decreased last week with two new deals announced and five pending deals closing. Deal Statistics: New Deals: The acquisition of Ellie Mae (ELLI) by Thoma Bravo for $3.7 billion or $99.00 per share in cash. The acquisition of CAS Medical Systems (CASM) by Edwar...
Biotech Pulse Biotech tumbled off a steep ski slope in the last quarter, and at the December low, the Nasdaq Biotechnology Index ( IBB ) had declined -28%, while the S&P Biotech Select Index ( XBI ) a whopping -36%. But it seems biotechs were able to regain their composure at the lows an...
On February 5, Array BioPharma has reported a stronger quarterly result for the company’s commercialized drug, BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib). Moreover, the Array’s FDA granted candidate, Beacon CRC, in the new data from Phase III study showed an overa...
Since I have last written on Array ( ARRY ), the stock price has risen from $13.43 to $20.96 at the close of the market on 2/5/19. While this is a nice gain, the fundamentals of the company have also improved, suggesting there is much more room for this Mid-Cap biotech to run. While my last ...
"A cynic is a man who, when he smells flowers, looks around for a coffin." - H.L. Mencken Stocks ended January on a high note with the major indices up just under one and half percent last week. It was the best start to a New Year since 1987 for investors after a dismal fourth quarter. T...
Merger activity increased last week with two new deals announced and eleven pending deals closing. Deal Statistics: New Deals: The merger of Versum Materials (VSM) and Entegris (ENTG) for $4.89 billion in an all-stock deal. Under the terms of the agreement, Versum Materials stoc...
INDIANAPOLIS and STAMFORD, Conn. , Feb. 1, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) ("Lilly") and Loxo Oncology, Inc. (NASDAQ: LOXO) ("Loxo Oncology") today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 197...
Recently, the ArQule’s lead candidate, derazantinib, showed positive preliminary action from a Phase 2 liver cancer study. In addition, ArQule reported that partner Basilea Pharmaceutica (OTC: BPMUF ) will team up with Roche (OTCQX: RHHBY ) to assess the combination of derazantinib,...
News, Short Squeeze, Breakout and More Instantly...
INDIANAPOLIS and STAMFORD, Conn. , Feb. 1, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) ("Lilly") and Loxo Oncology, Inc. (NASDAQ: LOXO) ("Loxo Oncology") today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 197...